Daniel Brennan, an analyst from TD Cowen, has initiated a new Buy rating on Personalis (PSNL).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Daniel Brennan has given his Buy rating due to a combination of factors including strong financial performance and promising future prospects. Personalis reported first-quarter sales that significantly exceeded expectations, driven by robust performance in their Pharma segment and favorable developments in their ImmunoID and NeXT Personal offerings. The company’s margins improved, and they maintained their guidance for 2025, which reflects a conservative approach from the pharmaceutical sector.
Additionally, Personalis’s ultra-sensitive MRD technology is gaining recognition, contributing to the stock’s substantial increase over the past year. The NeXT Personal platform is backed by clinical evidence across multiple indications, and the company is making progress with its MRD strategy and timelines. Recent interim results from the VICTORI study in colorectal cancer are promising, and the company has submitted for coverage in breast cancer. With growing optimism about Personalis’s MRD opportunities and a solid pharma business, Brennan sees a favorable outlook for the stock, initiating a price target of $7.
Brennan covers the Healthcare sector, focusing on stocks such as Waters, NeoGenomics, and Exact Sciences. According to TipRanks, Brennan has an average return of 8.0% and a 40.75% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $7.00 price target.